Tin mới nhất

vade

DAPA HF: Dapagliflozin Offers New HF Therapy, Even Sans Diabetes

The diabetes drug dapagliflozin (Farxiga, AstraZeneca) provides substantial benefits among patients with chronic heart failure with reduced ejection fraction (HFrEF) -even in those without diabetes, according to the DAPA HF trial. The sodium-glucose cotransporter 2 (SGLT2) inhibitor reduced the relative risk for the primary outcome – a composite of time …

Xem chi tiết